ClinicalTrials.gg
Status unknownNCT05284357Updated Aug 12, 2022

Post Market Clinical Follow-up Study for Arthroplasty Shoulder System of FX Solutions at the Long Term

An observational study in Shoulder Disease, Shoulder Fractures and Shoulder Arthroplasty for Revision of Previous Treatment, sponsored by FX Solutions. Status unknown at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by FX Solutions · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
416
Ages
18 Years and older
Sex
All
01

Study summary

This study takes place in the framework of the Post-Market Clinical Follow-up of the FX Solutions Shoulder System. The goal of this PMCF study is to collect clinical data in order to confirm the safety and the performance at a long term and mainly the first two years of sales for each studied ranges.

Eligible patients who received the FX Solutions Shoulder System and are at about 7 years post-operative were contacted by the Investigator to explain the study, the retrospective collection and the prospective follow-up visit. Investigator also explain the analysis of the post-operative outcomes of the patient. During the call of the investigator, the patient was informed about the study's goal and about the data collection. The oral agreement of the patient was checked by the investigators in CRF with its signature. Then, an information form explaining the purpose of the data collection was provided to the patient by postmail.

The retrospective data were collected in a paper CRF via the medical file of patient.

Post-operative follow-up for all patients is limited to a teleconsultation intended to assess the patient's current condition and clinical outcomes.

Patient who are enrolled in the study shall be assigned a unique Subject Identification Number to de-identify their information.

Read the detailed description

Inclusion Criteria

  • Adult patient (≥ 18 years old) who received one of FX Solutions Shoulder System for indication of hemi or total shoulder replacement.
  • Patient implanted between 2011 and 2015 with a minimum follow-up of 7 years
  • Patient has been informed of his participation in a clinical study and did not object to data collection
  • Patient insured with a social security system

Exclusion Criteria

  • Patient who does not meet the inclusion criteria above
  • Protected adult
  • People deprived of their liberty

Study Objectives

  • Primary Objective: To assess functional improvement according to the Constant score evolution compared to its preoperative value
  • Secondary Objectives, assessment of:

To assess against the preoperative value:

  • the Subjective Shoulder Value score evolution
  • the American Shoulder and Elbow Surgeons shoulder score evolution To describe in real life
  • The complications rate
  • The long-term range of motion
  • The revision rates and the prosthesis survival curve

Endpoints

  • Primary Endpoint will be the current Constant score (measured during the assessment). The functional improvement will be evaluated according to the evolution of this score compared to its preoperative value.
  • Secondary Endpoints:

Current ASES and SSV scores Current range of Motion Revision rate at a long-term follow-up. Calculation of the survival rates The incidence of complications occurring since implantation Revision rates and survival rates of prostheses

Study Groups Group 1: Subjects implanted with HUMELOCK I \& II® Anatomic Shoulder System 2011 to 2013 Group 2: Subjects implanted with HUMELOCK II® Reversible System 2011 to 2013 Group 3: Subjects implanted with HUMELOCK Reversed® Shoulder System - 2012 - 2013 Group 4: Subjects implanted with EASYTECH® Anatomic Shoulder System - 2013 - 2014 Group 5: Subjects implanted with EASYTECH® Reversed Shoulder System (For Primary intention only) - 2013- 2014 Group 6: additional group for Subjects who were implanted with EASYTECH® Reversible Shoulder System (Exclusively for Revision of Easytech Anatomic) - 2013 -2014, if applicable Group 7: Subjects implanted with HUMERIS® Anatomic Shoulder System 2014 to 2015 Group 8: Subjects implanted with HUMERIS® Reversible Shoulder System 2014 to 2015

02

Conditions studied

  • Shoulder Disease
  • Shoulder Fractures
  • Shoulder Arthroplasty for Revision of Previous Treatment

Browse trials for

03

In context

Shoulder Fractures

113 studies on the registry are indexed under Shoulder Fractures; 30 are open to participants now.

This study's planned enrollment of 416 is above the median of 97 across 60 observational studies indexed under Shoulder Fractures.

Browse Shoulder Fractures studies →

Lead sponsor

FX Solutions is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Studied devices are intended for adult population that are treated for arthroplasty with the studied devices. These patients are presented a pathologic shoulder pain with origin with degeneration or trauma of the articulation pathologies.

This study will include adult male and female patients from the Investigators' practice who were implanted with the FX Solution System; inclusion and exclusion criteria are defined not to introduce a too important bias of selection.

The selected patients may be representative the overall population that could treated with devices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

First of all, in order to be eligible to the study protocol, patients should have been treated primarily with one of studied device depending on surgeons' strategies' cares.

In order to be eligible to participate in this study, patients must meet all of the following criteria:

  • Adult patient (≥ 18 years old) who received one of FX Solutions Shoulder System for indication of hemi or total shoulder replacement.
  • Patient implanted between 2011 and 2015 with a minimum follow-up of 7 years
  • Patient has been informed of his participation in a clinical study and did not object to data collection
  • Patient insured with a social security system

Exclusion criteria

Exclusion criteria for subject selection.

  • Patient who does not meet the inclusion criteria above
  • Protected adult
  • People deprived of their liberty
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
416 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Subjects implanted with HUMELOCK I & II® Anatomic Shoulder System

    The number of patients implanted was defined by comparing sales' database of FX Solutions. 97 patients were identified who could be included in this cohort in 11 investigational centers. subjects implanted in 2011 to 2013

    Device: Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System

  • Group 2: Subjects implanted with HUMELOCK II® Reversible System

    The number of patients implanted was defined by comparing sales' database of FX Solutions. Number of patient to be determined following patients files in 4 investigational centers. subjects implanted in 2011 to 2013

    Device: Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System

  • Group 3: Subjects implanted with HUMELOCK Reversed® Shoulder System

    The number of patients implanted was defined by comparing sales' database of FX Solutions. 154 patients were identified who could be included in this cohort in 5 investigational centers. subjects implanted in 2012 and 2013

    Device: Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System

  • Group 4: Subjects implanted with EASYTECH® Anatomic Shoulder System

    The number of patients implanted was defined by comparing sales' database of FX Solutions. 66 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014

    Device: Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System

  • Group 5: Subjects implanted with EASYTECH® Reversed System (Primary intention)

    The number of patients implanted was defined by comparing sales' database of FX Solutions. 7 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014

    Device: Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)

  • Group 6:Subjects implanted with EASYTECH® Reversible System (Revision of Easytech Anatomic)

    The number of patients implanted was defined by comparing sales' database of FX Solutions. the number of subjects will depend of revised subjects primary implanted with Easytech Anatomic® along the dedicated period subjects implanted in 2013 to 2014

    Device: Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)

  • Group 7: Subjects implanted with HUMERIS® Anatomic Shoulder System

    The number of patients implanted was defined by comparing sales' database of FX Solutions. 11 patients were identified who could be included in this cohort in 3 investigational centers Subjects implanted in 2014 to 2015

    Device: Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System

  • Group 8: Subjects implanted with HUMERIS® Reversible Shoulder System

    The number of patients implanted was defined by comparing sales' database of FX Solutions. 72 patients were identified who could be included in this cohort in 2 investigational centers Subjects implanted in 2014 to 2015

    Device: Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System

Interventions

  • DeviceShoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System

    HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia. The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis.

  • DeviceShoulder Arthroplasty Surgery with HUMELOCK II® Reversible System

    HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II reversible system is used when the rotator cuff is injured.

  • DeviceShoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System

    Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)

  • DeviceShoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System

    EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis. EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability

  • DeviceShoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)

    EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear. EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation

  • DeviceShoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)

    EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear. EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation.

  • DeviceShoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System

    The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.

  • DeviceShoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System

    The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible

06

What researchers measure

Primary outcomes

  1. Clinical outcomes

    Functional scores measurement with Constant-Murley's Score

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  2. Articular functional measurement scores

    measurement with American Shoulder and Elbow Surgeons Shoulder Score (ASES)

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  3. subjective evaluation by the patient of shoulder function

    Measurement with subjective shoulder value (SSV)

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

Secondary outcomes

  1. Range of Motion scores

    Measurement of shoulder mobility (constant score)

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  2. Revision rate

    Number of patients with a change of implants out of the total number of patients reviewed in the study

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  3. Rate of complication

    All complications that had occurred will be collected in the CRF

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  4. Last information for patient lost to follow-up

    All available information about patients during his last medical follow-up

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  5. Survival rate

    Kaplan-Meier curve

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

  6. Last information for deceased patient

    All available information about patients before his death

    Time frame: between 6 and 10 years depending on the date of implantation of the medical device in each treatment group

07

Study locations

20 of 20 sites recruiting
  • Hôpital Privé Antony
    Antony, 92160, France
    Recruiting
  • CHU Jean MINJOZ
    Besançon, 25000, France
    Recruiting
    • Laurent OBERT, MD · Contactlobert@chu-besancon.fr · +33 3 81 66 82 85
    • Laurent OBERT, MD · Principal investigator
  • Centre hospitalier Bourg en Bresse
    Bourg-en-Bresse, 01000, France
    Recruiting
    • Samuel FERRY, MD · Contactsferry@ch-bourg01.fr · +33 4 74 45 46 47
    • Samuel FERRY, MD · Principal investigator
  • Clinique Convert
    Bourg-en-Bresse, 01000, France
    Recruiting
    • Pascal CLAPPAZ, MD · Contactclappaz@ymail.com · +33 4 74 45 64 03
    • Pascal CLAPPAZ, MD · Principal investigator
  • Infirmerie Protestante
    Caluire-et-Cuire, 69300, France
    Recruiting
  • Hopital privé Sainte Marie
    Chalon-sur-Saône, 71110, France
    Recruiting
    • Hugues DELASELLE, MD · Contacth.delaselle@ramsaygds.fr · +33 3.85.97.81.91
    • Hugues DELASELLE, MD · Principal investigator
  • CHMS Chambéry
    Chambéry, 73011, France
    Recruiting
  • Clinique La Montagne
    Courbevoie, 92400, France
    Recruiting
    • Marc JUVENSPAN, MD · Contactm.juvenspan@gmail.com · +33 1 86 86 56 56
    • Marc JUVENSPAN, MD · Principal investigator
  • Centre Hospitalier de Dieppe
    Dieppe, 7620, France
    Recruiting
    • Claire Cordier, MD · Contactccfuzeau@gmail.com · +33 2 32 14 76 76
    • Claire Cordier, MD · Principal investigator
  • Clinique Saint Charles
    Lyon, 69001, France
    Recruiting
    • Thierry AUTHOM, MD · Contactthauthom@gmail.com · +33 4 26 84 20 23
    • Thierry AUTHOM, MD · Principal investigator
  • Clinique de l'Occitanie
    Muret, 31600, France
    Recruiting
    • Yves Bellumore, MD · ContactBellumore.y@orange.fr · +33 5 61 51 89 09
    • Yves Bellumore, MD · Principal investigator
  • Clinique Jouvenet
    Paris, 75016, France
    Recruiting
  • Clinique des Maussins
    Paris, 75020, France
    Recruiting
    • Geoffroy NOURISSAT, MD · Contactgnourissat@wanadoo.fr · +33 1 42 03 47 37
    • Geoffroy NOURISSAT, MD · Principal investigator
  • CHI Poissy - St Germain en Laye
    Poissy, 78300, France
    Recruiting
  • Hopital Privé Claude Gallien
    Quincy-sous-Sénart, 91480, France
    Recruiting
    • Éric LENOBLE, MD · Contacteric.lenoble@wanadoo.fr · +33 1 69 39 91 46
    • Éric LENOBLE, MD · Principal investigator
  • Clinique Mutualiste la Sagesse
    Rennes, 35000, France
    Recruiting
  • Centre Hospitalier de St Malo
    Saint-Malo, 35400, France
    Recruiting
  • Clinique Saint Léonard
    Trélazé, 49800, France
    Recruiting
  • Clinique Bergouignan
    Évreux, 27000, France
    Recruiting
  • Centre Hospitalier Princesse Grace
    Monaco, 98000, Monaco
    Recruiting
    • Tristan LASCAR, MD · Contacttristan.lascar@chpg.mc · +377 97 98 97 14
    • Tristan LASCAR, MD · Principal investigator
08

References and documents

Publications

  • Churchill RS. Stemless shoulder arthroplasty: current status. J Shoulder Elbow Surg. 2014 Sep;23(9):1409-14. doi: 10.1016/j.jse.2014.05.005. Epub 2014 Jul 11. PubMed 25027481 ↗
  • Cuff D, Pupello D, Virani N, Levy J, Frankle M. Reverse shoulder arthroplasty for the treatment of rotator cuff deficiency. J Bone Joint Surg Am. 2008 Jun;90(6):1244-51. doi: 10.2106/JBJS.G.00775. PubMed 18519317 ↗
  • De Wilde LF, Audenaert EA, Berghs BM. Shoulder prostheses treating cuff tear arthropathy: a comparative biomechanical study. J Orthop Res. 2004 Nov;22(6):1222-30. doi: 10.1016/j.orthres.2004.03.010. PubMed 15475201 ↗
  • Frankle M, Levy JC, Pupello D, Siegal S, Saleem A, Mighell M, Vasey M. The reverse shoulder prosthesis for glenohumeral arthritis associated with severe rotator cuff deficiency. a minimum two-year follow-up study of sixty patients surgical technique. J Bone Joint Surg Am. 2006 Sep;88 Suppl 1 Pt 2:178-90. doi: 10.2106/JBJS.F.00123. PubMed 16951091 ↗
  • Franklin JL, Barrett WP, Jackins SE, Matsen FA 3rd. Glenoid loosening in total shoulder arthroplasty. Association with rotator cuff deficiency. J Arthroplasty. 1988;3(1):39-46. doi: 10.1016/s0883-5403(88)80051-2. PubMed 3361319 ↗
  • Hawi N, Magosch P, Tauber M, Lichtenberg S, Habermeyer P. Nine-year outcome after anatomic stemless shoulder prosthesis: clinical and radiologic results. J Shoulder Elbow Surg. 2017 Sep;26(9):1609-1615. doi: 10.1016/j.jse.2017.02.017. Epub 2017 Apr 11. PubMed 28410956 ↗
  • Hawi N, Tauber M, Messina MJ, Habermeyer P, Martetschlager F. Anatomic stemless shoulder arthroplasty and related outcomes: a systematic review. BMC Musculoskelet Disord. 2016 Aug 30;17(1):376. doi: 10.1186/s12891-016-1235-0. PubMed 27577859 ↗
  • Jazayeri R, Kwon YW. Evolution of the reverse total shoulder prosthesis. Bull NYU Hosp Jt Dis. 2011;69(1):50-5. PubMed 21332439 ↗
  • Lugli T. Artificial shoulder joint by Pean (1893): the facts of an exceptional intervention and the prosthetic method. Clin Orthop Relat Res. 1978 Jun;(133):215-8. PubMed 357063 ↗
  • NEER CS 2nd. Articular replacement for the humeral head. J Bone Joint Surg Am. 1955 Apr;37-A(2):215-28. No abstract available. PubMed 14367414 ↗
  • Neer CS 2nd, Craig EV, Fukuda H. Cuff-tear arthropathy. J Bone Joint Surg Am. 1983 Dec;65(9):1232-44. PubMed 6654936 ↗
  • Neer CS 2nd, Watson KC, Stanton FJ. Recent experience in total shoulder replacement. J Bone Joint Surg Am. 1982 Mar;64(3):319-37. No abstract available. PubMed 7061549 ↗
  • Post M, Jablon M, Miller H, Singh M. Constrained total shoulder joint replacement: a critical review. Clin Orthop Relat Res. 1979 Oct;(144):135-50. PubMed 535215 ↗

Individual participant data

Plan to share: No — No plan to share IDP for this study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Oct 2022, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Mar 17, 2022
StartActual
Apr 7, 2022
Primary completionEst.
Oct 2022
CompletionEst.
Oct 2022
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05284357
Lead sponsor
FX Solutions
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Apr 7, 2022
Primary completion
Oct 2022 (estimated)
Completion
Oct 2022 (estimated)
Last update
Aug 12, 2022

Study contacts

Cédric FERRY
Contact
clinique@fxsolutions.fr
+33 6 09 25 13 13
Carole CARRÉ
Contact
clinique@fxsolutions.fr
+33 6 09 25 38 08
Laurent OBERT, MD
principal investigator · CHU Jean MINJOZ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion